The tumor necrosis factor-alpha gene (TNFA) is characterized by several single nucleotide polymorphisms (SNPs) in its promoter region. Interestingly, some of these SNPs appear to influence TNFA expression and susceptibility to various human diseases, but the molecular mechanisms by which such possibly functional SNPs modulate TNFA expression are poorly understood. In this study, we show allele-specific binding of the ubiquitous transcription factor OCT-1 to the SNP sites at positions −863 and −857 in the promoter, which appear to affect TNFA expression: the protein was associated with variant allele possessing either −863A or −857T, but rarely with the common allele (−863C and −857C). The evidence presented here, therefore, suggests the possibility that OCT-1 could contribute to the modulation of TNFA expression by means of its allele-specific binding manner. Genes and Immunity (2000) 2, 105-109.
Tumor necrosis factor-alpha (TNF-␣) is a cytokine, which has multiple functions in the immune response, eg, activation of macrophages, induction of apoptosis, and protection against microbial infections. The gene (TNFA) is located in the human leukocyte antigen (HLA) class III region, and possesses several single nucleotide polymorphisms (SNPs) in its promoter region. [1] [2] [3] [4] Notably, some of the SNPs appear to affect TNFA expression 3, [5] [6] [7] and to be associated with the susceptibilities to various human diseases including autoimmune and infectious diseases [8] [9] [10] [11] [12] and a sleep disorder. 13 Although the molecular mechanisms, by which possibly functional SNP sites influence TNFA expression, are poorly understood, the associations of nuclear factors (proteins) with such SNP sites have been detected. It seems that such interactions between nuclear proteins and the SNP sites provide us with significant information for understanding the allele-specific modulation of the TNFA expression. Knight et al (1999) 12 have shown that OCT-1 transcription factor is associated with the SNP site at position −376, which appears to affect TNFA expression: the −376A allele appears to enhance the TNFA expression as compared with the −376G allele, and to be associated with OCT-1. Unknown proteins associated with possibly functional SNP sites at positions −308 and −863 in the promoter have also been detected. 6, 7 In this study, we focused on the −857SNP and its adjacent −863SNP, because they are both possibly functional SNP sites in the TNFA promoter, and because they appeared to be associated with the susceptibilities to various human diseases; eg, a significant association of the −857T allele with either narcolepsy 13 or diabetes mellitus, 14 and of the −863A allele with Crohn's disease. 15 Regarding the influence of these SNPs on TNFA expression, Higuchi et al (1998) 3 carried out a detailed transfection analysis using Raji cell (a human B-cell line) and a transgene, in which the TNFA promoter region containing −857 and −863SNPs was linked to a reporter gene (the firefly luciferase gene), and demonstrated that the promoter with either −857T or −863A significantly enhanced transcriptional activity as compared with that of the promoter containing −857C and −863C in response to Con A stimulation. They also showed that the level of TNF-␣ production in Con A-activated peripheral blood mononuclear cells carrying either −857T or −863A was significantly higher than that of Con A-activated mononuclear cells carrying −857C and −863C.
3 These observations suggest that variant alleles, −857T and −863A, could impart an upregulation to TNFA expression and increase predisposition to the diseases described above, and then lead us to the presumption that nuclear proteins could be associated with these SNPs and implicated in the modulation of TNFA expression.
In order to examine if there were any nuclear factors associated with the −857 and/or −863 SNPs in the TNFA Figure 2 Competition assay. Ten-(10×) and 100-fold (100×) excess amounts of cold oligonucleotides (CT, AC and CC) against the probe used (0.07 pmol) were incubated with LCL nuclear extracts. After 5 min incubation, radiolabelled oligonucleotide probes (CT or AC probe) were added into the reaction mixtures and the standard EMSA with 5% polyacrylamide gels was carried out as in Figure 1 . Similar results were obtained when HeLa nuclear extracts were used in place of LCL extracts (data not shown). Complex I is indicated by arrows. 20 The LCL nuclear extract was prepared as previously described, 21 and dialyzed against buffer containing 20 mm HEPES, pH 7.9, 100 mm KCl, 0.2 mm EDTA, 0.5 mm DTT, 0.5 mm PMSF and 20% glycerol at 4°C. The HeLa nuclear extract was purchased from Promega. The sequences of the double-stranded oligonucleotides used as probes are as follows: CC, 5Ј-GGACCCCCCCTTAACGAAGACAGGGCCATG-3Ј; AC, 5Ј-GGACCCCCACTTAACGAAGACAGGGCCATG-3Ј; CT, 5Ј-GGACCCCCCCTTAATGAAGACAGGGCCATG-3Ј. The oligonucleotides were 32 P-end-labelled with [␥-32 P] ATP and T4 DNA kinase (Promega). The labelled probes [ෂ0.07 pmol (ෂ200000 CPM)/reaction] were incubated with LCL and HeLa nuclear extracts in gel shift binding buffer [10 mm Tris-HCl, pH 7.5, 50 mm NaCl, 1 mm MgCl2, 0.5 mm EDTA, 0.5 mm DTT, 50 ng/ml poly(dIdC)] at room temperature for 20 min. After incubation, the reactions were electrophoretically separated on 4% polyacrylamide gel containing 1×TBE buffer at room temperature, and exposed to X-ray film. Arrow I indicates complex I.
promoter, we carried out electrophoretic mobility shift assay (EMSA) with synthesized oligonucleotides containing both −863 and −857 SNPs as probes. Since three haplotypes carrying the −863 and −857 SNPs have been found, 3, 16 we designed three oligonucleotides corresponding to the haplotypes for EMSA: CC oligonucleotide was designed from the common haplotype, −863C to −857C; AC oligonucleotide from one of the variant haplo-types, −863A to −857C; CT oligonucleotide from the other variant haplotype, −863C to −857T. These oligonucleotides were 32 P-labelled, incubated with nuclear extracts prepared from HeLa and lymphoblastoid cell line (LCL), and examined by EMSA. The results of EMSA are shown in Figure 1 . As shown in the figure, protein-oligo DNA complexes were detected using these probes on either the HeLa or LCL nuclear extract. When the EMSA profiles were compared with one another, we found complex I (indicated by arrow I in Figure 1 ) in the EMSA profiles using CT and AC oligonucleotide probes on either the HeLa or LCL nuclear extract. Interestingly, complex I was scarcely detected in the EMSA profile with the CC oligonucleotide probe used. These results indicate that the nuclear protein(s) bound to the variant alleles (CT and AC probes) but not to the common allele (CC probe) occurs in HeLa and LCL nuclear extracts. We add that dialysis of the nuclear extracts (see Figure 1 legend) appears to be indispensable for the allele-specific binding of protein(s) in the formation of complex I with either CT or AC oligonucleotide probe: nonallele-specific binding of protein(s) in the formation of complex I was observed when undialyzed nuclear extracts were used in EMSA (data not shown).
In order to confirm the specificity of complex I for the CT and AC oligonucleotides, a competition assay was carried out using excess amounts of cold oligonucleotides as competitors. As shown in Figure 2 , the formation of complex I with either the radiolabelled CT or AC oligonucleotide probe was efficiently inhibited by cold CT and AC oligonucleotides. In contrast, weak competition was seen when the CC oligonucleotide was used as the com- Genes and Immunity petitor. These observations, therefore, suggest that there is a sequence-specific association between the probe DNA and protein(s) in the formation of complex I, and that the same protein(s) probably participates in the complex I formation together with either the CT or AC oligonucleotide, because cold AC oligonucleotide efficiently competed with the radiolabelled CT oligonucleotide probe in the complex I formation and vice versa.
Next, we attempted to identify the protein(s) involved in the complex I formation together with the CT or AC oligonucleotide. To address this, we examined the sequences of the oligonucleotide probes with the aid of the TFSEARCH computer program, 17 which searches highly correlated sequence fragments against the TFMA-TRIX transcription factor binding site profile database in the TRANSFAC databases by GBF-Braunschweig. 18 When the search was carried out, it was found that the base substitutions of T for C at position −857 and of A for C at position −863 could generate a putative binding site for OCT-1. 19 The results of EMSA using HeLa and LCL nuclear extracts (Figure 1 ) suggested that the protein(s) of complex I was likely present in various kinds of cells, ie, was present ubiquitously, and that the same protein(s) probably participated in the formation of complex I with either the CT or AC oligonucleotide. From these observations, we examined whether the ubiquitous transcription factor OCT-1 contributed to the formation of complex I.
Competition EMSA using OCT-1 and NF-B consensus oligonucleotides as competitors was carried out. The results of the competition assay (Figure 3) showed that the OCT-1 consensus oligonucleotide strongly inhibited the formation of complex I with either the CT or AC oligonucleotide probe, whereas no competition was observed in the presence of the NF-B consensus oligonucleotide used as the competitor, indicating that OCT-1 participates in the formation of complex I. To further confirm the results, we performed a super-shift assay with anti-human OCT-1 antibody. As shown in Figure 4 , when anti-human OCT-1 antibody was added into the reaction mixture containing either the CT or AC oligonucleotide probe, the band corresponding to complex I disappeared and the super-shifted band due to the antibody binding to complex I appeared (indicated by arrow II in Figure  4) , whereas no such band change was seen in the treatment with anti-His 6 antibody used as the negative control. When the reaction mixtures containing the CC oligonucleotide probe were incubated with these antibodies, slight or no band change was observed. Altogether, the data of the super-shift and competition assays show that OCT-1 is a constituent molecule of complex I, and that OCT-1 is associated with the −863 and −857 SNP sites in the TNF promoter in an allele-specific manner.
A faint band with a little faster mobility than that of complex I appeared (indicated by open arrowheads in Figures 3 and 4) , when the reaction mixtures containing the CT oligonucleotide probe were treated with OCT-1 consensus oligonucleotide and anti-OCT-1 antibody. The complex appeared to be specific for the CT oligonucleotide, and OCT-1 may influence the formation of the complex. Studies as to what kind of proteins are involved in the complex formation would be of interest. Knight et al (1999) 12 have already shown the allelespecific binding of OCT-1 to the SNP site at position −376 in the TNFA promoter. Together with the present data, at least three possibly functional SNP sites in the TNFA promoter appear to be associated with OCT-1. These observations lead to the possibility that OCT-1 could contribute to the modulation of TNFA expression by means of its allele-specific binding manner. Accordingly, differences in the TNFA expression due to the allele-specific binding of OCT-1 to these SNP sites maybe contribute to the susceptibilities to various human diseases. Since the interaction of OCT-1 with other proteins likely confers variations in gene expression, studies as to if there are any proteins associated with OCT-1 at these SNP sites in the TNFA promoter would be of interest and remain to be conducted.
